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Conformational thermostabilisationThe tetracycline antiporter TetA(B) is a member of the Major Facilitator Superfamily which confers tetracycline
resistance to cells by coupling the efﬂux of tetracycline to the inﬂux of protons down their chemical potential gra-
dient. Although it is a medically important transporter, its structure has yet to be determined. One possibility for
why this has proven difﬁcult is that the transportermay be conformationally heterogeneous in the puriﬁed state.
To overcome this, we developed two strategies to rapidly identify TetA(B)mutants that were transport-defective
and that could still bind tetracycline. Up to 9 amino acid residues could be deleted from the loop between trans-
membraneα-helices 6 and 7with only a slight decrease in afﬁnity of tetracycline binding asmeasured by isother-
mal titration calorimetry, although the mutant was transport-defective. Scanning mutagenesis where all the
residues between 2 and 389 were mutated to either valine, alanine or glycine (VAG scan) identiﬁed 15 mutants
that were signiﬁcantly impaired in tetracycline transport. Of these mutants, 12 showed no evidence of
tetracycline binding by isothermal titration calorimetry performed on the puriﬁed transporters. In contrast, the
mutants G44V and G346V bound tetracycline 4–5 fold more weakly than TetA(B), with Kds of 28 μM and
36 μM, respectively, whereas the mutant R70G bound tetracycline 3-fold more strongly (Kd 2.1 μM). Systematic
mutagenesis is thus an effective strategy for isolating transporter mutants that may be conformationally
constrained and which represent attractive targets for crystallisation and structure determination.
© 2015 MRC Laboratory of Molecular Biology. Published by Elsevier B.V. This is an open access article under the
CC BY license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
Bacterial resistance to tetracycline arises from the expression of any
one of at least 23 known tetracycline transporters, which couple export
of tetracycline to the inﬂux of protons down their electrochemical gra-
dient [1]. Of these tetracycline antiporters, TetA(B), a member of the
major facilitator superfamily (MFS), has the widest host range in
Gram-negative bacteria. [2]. MFS transporters are comprised of twelve
transmembrane α-helices arranged in two bundles of six helices (heli-
ces 1–6 and 7–12), which are thought to have arisen from a gene dupli-
cation that, in turn, was the result of a duplication of a three-helix motif
[3]. Crystal structures of 17members of theMFS are available in a num-
ber of conformations [4–29]. Generally, the approach taken has been to
express hundreds of transporter homologs and to work on those that
are most highly expressed and most stable in detergent, rather than
the most therapeutically relevant. So, although the MFS family has
been extensively studied, there are no available crystal structures forolecular Biology, Cambridge
0QH, UK.
ge Science Park, Cambridge CB4
Published by Elsevier B.V. This is an oclose homologs of TetA(B) and hence it is desirable that this transporter
be crystallised and examined in molecular detail.
TetA(B) was the ﬁrst drug resistance transporter discovered [30]
and was shown to confer the exchange of a tetracycline-Mg2+ adduct
and a proton [31,32]. Each amino acid residue of TetA(B) has been
systematically mutated to cysteine and the mutants were used to esti-
mate the solvent exposure of side chains by measuring the ability of
N-ethylmaleimide (NEM) to label the mutated transporter [33–39].
These data also identiﬁed mutations at 17 positions that resulted in a
signiﬁcant reduction in tetracycline resistance. Currently the only struc-
tural data available are from 2-dimensional crystals of TetA(B), but the
data are at low resolution (~17 Å) [40]. 3-Dimensional crystals have
not yet been reported, suggesting that the conformational dynamics
and/or the stability of the detergent-solubilised transporter may be
preventing the formation of well-diffracting crystals, and hence in this
work an alternative strategy was tested in efforts to improve the prob-
ability of crystal formation.
One possibility to increase the likelihood of crystallising TetA(B) is to
introduce mutations into the transporter that decrease conformational
dynamics and also possibly improve thermostability. This strategy,
termed conformational thermostabilisation [41], has been very success-
ful for membrane protein crystallography, in particular for G protein-
coupled receptors (GPCRs) [42,43]. The identiﬁcation of mutationspen access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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possible using a radioligand-binding assay, coupled to systematic mu-
tant generation [42]. These mutations increased the stability of the pro-
tein in all detergents tested, thus allowing crystallisation trials to be
performed in even short chain denaturing detergents such as
nonylglucoside and octylthioglucoside [41]. Thermostabilising muta-
tions in GPCRs selected using a radiolabelled antagonist resulted in a
thermostabilised receptor preferentially found in an antagonist binding
conformation, as shown by the afﬁnity for antagonists that was un-
changed, whereas the afﬁnity for agonists was orders of magnitude
weaker than for the wild type receptor. Therefore, selection using a
radioligand-binding assay resulted in a membrane protein with in-
creased thermostability and a conformational bias [42].
Conformational thermostabilisation has also been successful for the
rat serotonin transporter (SERT) [44]. The thermostabilisedmutant was
over 17 °Cmore stable than the wild type transporter and it was locked
in an outward-facing conformation that bound the cocaine-analogue
RTI55 with high afﬁnity and also the substrate serotonin with similar
afﬁnity to the wild type transporter. However, although the mutated
transporter could bind inhibitors and substrate, it could not transport
3H-serotonin, suggesting that the transporter was indeed heavily biased
towards a single conformation. Interestingly, the majority of the
thermostabilising mutations were predicted to be at the interfaces be-
tween transmembrane α-helices and, in particular, within or adjacent
to regions where the α-helices were kinked or were not helical.
One of the problemswith conformational thermostabilisation is that
the radioligand binding assays require high afﬁnity natural substrates
or inhibitors (in the nM range). However, the substrates of many
secondary transporters, such as TetA(B), are of much lower afﬁnity
(μM–mM) and so the current methodology as applied to GPCRs will
be difﬁcult to implement with many transporters. There is therefore a
need for a technique analogous to conformational thermostabilisation
that can be employed for all secondary transporters. The approach
used here was based on the observation that the thermostabilised sero-
tonin transporter was incapable of functioning as a transporter, despite
being able to bind substrate [44]. Thus selecting for mutants that
prevented substrate transport but which still allowed substrate binding
with an afﬁnity similar to the wild type transporter would result in a
transporter with properties more suitable for structural studies i.e.
biased towards a single conformation.
Two methodologies were employed in this work to identify muta-
tions that biased the conformation of TetA(B). Firstly, deletions in the
non-conserved loop between transmembrane helices 6 and 7 were
made to prevent the conformational change between outward-open
and inward-open states. The second approach involved the selection
of conformationally restrained mutants of TetA(B) using phenotypic
selection, in combination with measurement of their expression
levels. Loop deletion mutants and systematic point mutants were then
analysed by isothermal titration calorimetry (ITC) to identify those
mutants that retained substrate binding capabilities, despite being
transport-defective, and therefore were likely to be conformationally
restrained.
2. Materials and methods
2.1. Constructs
TetA(B) was cloned as a C-terminal enhanced GFP (eGFP) fusion
in pBluescript SKII (+) in the orientation so that it was expressed
from the lacUV5 promoter. PCR was performed with the templates
transposon Tn10 and a gene fusion provided by Dr. J Andréll for
TetA(B) and eGFP respectively in 0.2 ml thin-walled 8-tube strips
(Thermoscientiﬁc), using KOD hot start polymerase (Novagen) and
the manufacturer's protocol. Primers were designed to ligate eGFP
between EcoRI and HindIII sites with T4 DNA ligase, before ligating
TetA(B) between the SacI and EcoRI sites, resulting in a transporterwith a C-terminal eGFP fusion. This resulted in TetA(B)-eGFP,
which was used for deletion mutagenesis.
The TetA(B) ITC constructs (TetA(B)-His10 or TetA(B)Δ394–401-
Thrombin-His10) were also inserted between the restriction sites
NdeI and HindIII, but in plasmid pET21b under the control of the T7
promoter. The construct TetA(B)-Δ394–401-TEV-His10-eGFP was
used for all the scanning mutagenesis experiments and was expressed
from the lacUV5 promoter in pBluescript; the construct contained an
additional C-terminal truncation of 8 residues with a tobacco etch
virus (TEV) protease cleavage site and decahistidine tag (His10) be-
tween TetA(B) and eGFP, which were introduced by PCR using
mismatched primers. Ligations were transformed into competent
Escherichia coli XL1 cells, colonies grown for 18 h shaking at 250 rpm
at 37 °C were picked, miniprepped and sequenced. Minipreps and
maxipreps were performed using QIAGEN kits and the standard proto-
cols provided. All restriction endonucleases and ligase were purchased
fromNewEngland Biolabs. Plasmidswere sequenced by Beckman Coul-
ter Genomics using a synthesised primer complimentary to an internal
site in eGFP (GGCCGTTTACGTCGCCGTCC) and standard primers com-
plementary to the T7 promoter and M13 reverse. Sequencing typically
achieved double coverage of the transporter and single coverage of
the C-terminal eGFP.
2.2. Site directed mutagenesis of TetA(B)
Mutagenesis of TetA(B) was performed to identify mutations that
were likely to increase crystallisation probability. OptimusPrimer 2.0
(propriety primer design software, Heptares Therapeutics) was used
to design degenerate mutagenic primers for the introduction of muta-
tions of 378 of the 401 residues (amino acids 2–379) of TetA(B). Each
amino acid was individually mutated to valine, alanine or glycine
(VAG) using the codon GBC, where B represents either C, G or T,
resulting in GCC (Ala), GGC (Gly) or GTC (Val) introduced at a 1:1:1
ratio.
These VAG primers (produced in 96-well format by Integrated DNA
Technologies) were used to introduce site-directed mutations into the
template TetA(B)-Δ394–401-TEV-His10-eGFP in pBluescript SKII(+)
by PCR using KOD hot start polymerase in 96-well thermowell (Costar)
plates. Reactionmixtures included 1 x KOD hot start polymerase buffer,
0.2 mM of each dNTP, 1.5 mM MgSO4, 9% (v/v) DMSO, 1 U KOD hot
start polymerase, template plasmid DNA at approximately 5 ng/μl and
0.2–0.4 μM of forward and reverse primers in a ﬁnal 50 μl reaction
volume. The PCR reaction consisted of an initial 5 min of melting at
95 °C, followed by 30–40 rounds of: melting at 95 °C for 30 s, annealing
at 50–60 °C for 30 s and extension at 70 °C for 10min. This was followed
by 20–30min at 70 °C to ensure all extension reactionswere completed.
The methylated template DNA was then digested by addition of 40
Units of DpnI (New England Biolabs) by incubation for at least 5 h at
37 °C. 10 μl of each product was added to freshly thawed 200 μl E. coli
JM109 cells in 96-well deep well blocks (VWR International Ltd),
incubated on ice for 30 min before being heat shocked in a water bath
for 90 s at 42 °C and incubated on ice for 5 min. 500 μl of SOB media,
pre-warmed at 37 °C, was then added and the cells were incubated at
37 °C shaking at 220 rpm for 1 h. The cells were harvested by centrifu-
gation, approximately 500 μl of the supernatant was removed and the
cell pellet was resuspended in the remaining supernatant of approxi-
mately 200 μl. This was then plated on 2× TY agar plates in either indi-
vidual 90 mm or on large 7 × 7 divided formats containing 100 μg/ml
ampicillin. Plates were then dried for 30–60 min and incubated for
18 h inverted at 37 °C.
For the introduction of truncations and deletions into TetA(B)-eGFP
in pBluescript, TetA(B)His10 and TetA(B)-Δ394–401-Thrombin-His12
an identical PCR reaction to that above was used. The primers were de-
signedmanually with similar Tm values to those used in pointmutagen-
esis; however nucleotides coding for residues to be truncated were
omitted from forward and reverse primers. This was followed by DpnI
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as listed above on individual 90 mm 2× TY agar plates containing
100 μg/ml ampicillin. Multiple colonies were picked into 5 ml 100 μg/ml
ampicillin in 2× TY, grown for 18 h at 37 °C shaking at 220–250 rpm,
miniprepped and sequenced.
2.3. Antibiotic resistance phenotypic assay of TetA(B) deletion mutants in
liquid media
The phenotype of each truncation mutant in the TetA(B)-eGFP
construct was analysed by growing cultures in liquid media to sta-
tionary phase and measuring the ﬁnal attained OD600. Colonies of
transformants in E. coli strain JM109 were picked into 5 ml 2× TY
media (16 g/l tryptone, 10 g/l yeast extract, 86 mM NaCl, pH 7.4)
containing 100 μg/ml ampicillin and grown for 18 h at 37 °C shaking
at 220 rpm. 5 μl of the overnight cultures was added to 1 ml of fresh
2× TY media containing 100 μg/ml ampicillin and either 0 μM, 2 μM,
5 μM, 10 μM, 20 μM, 30 μM or 50 μM tetracycline (in triplicate) in 96-
deep well plates and grown at 220 rpm at 37 °C for 18 h. 200 μl sam-
ples were transferred to a 96-well plate Nunclon ﬂat-bottomed black
plate (Sigma Aldrich) and the cell density (OD600) was measured
using the Tecan Saﬁre II and compared to JM109 cells transformed
with wild type TetA(B)-eGFP in pBluescript SKII(+) as a positive
control and pBluescript containing no insert as a negative control.
Expression of TetA(B) relied on leaky expression from the lacUV5
promoter in the absence of IPTG.
2.4. High-throughput antibiotic resistance phenotypic assay of
TetA(B) site-directed point mutants
From the bacterial colonies produced from VAG scanning muta-
genesis, 8 colonies were picked for each amino acid position in
order to, on average, pick at least one of each of alanine, glycine
and valine-encoding codons. These colonies were picked into 1 ml
2× TY media (16 g/l tryptone, 10 g/l yeast extract, 86 mM NaCl,
pH 7.4) containing 100 μg/ml ampicillin in 96-well deep well blocks
and grown for 18 h at 37 °C shaking at 220 rpm. 5 μl of each culture
was used to inoculate 1 ml of 2× TY containing 100 μg/ml ampicillin
and either 0 μM or 36 μM tetracycline in 96-well deep well blocks.
These colonies were then grown for 18 h shaking at 220 rpm at
37 °C and the cell density (OD600) of 200 μl was measured using
the Tecan Saﬁre II in a 96-well Nunclon ﬂat-bottomed black plate
(Sigma Aldrich), which was compared to wild type transporter as a
positive control and vector containing no insert as a negative control.
Expression of TetA(B) relied on leaky expression from the lacUV5
promoter in the absence of IPTG.
2.5. Liquid growth antibiotic resistance phenotypic assay of initial hits of
TetA(B) site-directed point mutants
Colonies that were signiﬁcantly less resistant to tetracycline as
judged by relative optical density of cells grown in 36 μM tetracycline
compared to cells grown in the absence of tetracycline were further
examined over a broader range of tetracycline concentrations. 5 μl of
tetracycline growth negative cultures from the 96-well plate containing
only 100 μg/ml ampicillin in 2× TY (16 g/l tryptone, 10 g/l yeast extract,
86 mM NaCl, pH 7.4) or from cultures grown for 18 h at 37 °C from
freshly transformed JM109 cells was then added to 1ml 2× TY contain-
ing 100 μg/ml ampicillin containing 0 μM, 5 μM, 9 μM, 18 μM, 36 μM,
72 μM or 144 μM tetracycline in 96-deep well plates and grown at
220 rpm at 37 °C for 18 h. 200 μl sampleswere taken and the cell density
(OD600) wasmeasured using the Tecan Saﬁre II and compared to JM109
cells transformed with wild type TetA(B)-Δ394–401-TEV-His10-eGFP
in pBluescript SKII(+) as a positive control and pBluescript containing
no insert as a negative control. Expression of TetA(B) relied on leaky ex-
pression from the lacUV5 promoter in the absence of IPTG.2.6. Measurement of expression of TetA(B) mutants by in-gel ﬂuorescence
1.5ml of JM109 cells expressing transporter-eGFP fusions grown for
18 h at 37 °C at 220–250 rpm either in 24-well plates or in sterile glass
tubes were harvested with a bench top Eppendorf 5424 centrifuge and
resuspended in 100 μl deionised water. The cells were then sonicated,
solubilised in SDS-PAGE buffer and analysed by SDS-PAGE on 4–20%
Tris-Glycine gels (Invitrogen). Unstained gels were visualised on a
Typhoon Trio (GE Healthcare) gel scanner with a green laser at
532 nm and expression levels of transporter-eGFP were compared to
JM109 cells transformed with wild type transporter-eGFP fusions in
pBluescript SKII(+) and pBluescript SKII(+) containing no insert.
2.7. Large-scale expression of TetA(B)His10 and TetA(B)-Δ394–401-Throm-
bin-His12
Expression of TetA(B)-His10 and TetA(B)-Δ394–401-Thrombin-
His12 constructs were optimized in E. coli strain C43 [45,46]. Fresh
transformations of each construct were made and plated on to 90 mm
2× TY 1.5% (w/v) agar plates containing 100 μg/ml ampicillin. Colonies
were picked into 10 ml of 2× TY containing 100 μg/ml ampicillin and
grown for 18 h in sterile test tubes at 37 °C and 250 rpm. 4 ml of
this bacterial culture was used to inoculate 1 l of 2× TY containing
100 μg/ml ampicillin in a 2 l conical ﬂask, which was incubated at
37 °C, shaking at 220 rpm in an Infors HT Multitron standard shaker
until the cell density reached an OD600 of 0.3–0.5. IPTG was added to
a ﬁnal concentration of 0.2 mM and the temperature was lowered to
27 °C for 4 h. Cells were harvested in 1 l centrifuge bottles (Beckman
Coulter) at 3063 ×g for 15min at 4 °C in a JLA-8.1000 rotor (Beckman
Coulter) in Avanti J-26 XP centrifuge (Beckman Coulter) and resus-
pended in 20 ml per litre of cells of 20 mM Tris pH 7.4 with protease
inhibitor tablets made up to manufacturer's speciﬁcations, which
were then frozen at−20 °C in 50 ml Falcon tubes.
2.8. Membrane isolation for transport assay and puriﬁcation
Frozen cells were thawed and lysed by 3 passages using an
Emulsiﬂex C3 high-pressure homogeniser (Avestin) at approximately
10,000 psi. Cell debris was removed by centrifugation in a Sorvall SS34
rotor at 27000 ×g for 45min (4 °C) in a Sorvall Evolution RC centrifuge.
Themembrane fraction of this supernatant was collected by centrifuga-
tion in a Ti45 rotor (Beckman Coulter) for 120min at 158,000 ×g (4 °C)
in an Optima L-100XPUltracentrifuge (Beckman Coulter). The resulting
supernatant was carefully removed and the pellet was resuspended in
20 mM Tris pH 7.4 with a homogenisation syringe (Samco), using
5 ml of buffer for every litre of starting culture. At this point aliquots
of membranes could be frozen for transport assays, although usually
the puriﬁcation protocol was continued directly from resuspended
membranes.
2.9. Ni2+-afﬁnity puriﬁcation of TetA(B)Δ394–401-Thrombin-His12 and
TetA(B)His10 derivatives in LMNG for ITC
Membranes produced from 2 l of cells were solubilised in 1%
LMNG (Affymetrix), 20 mM Tris pH 7.7, 20 mM MgCl2 and 20 mM
NaCl and incubated for 2 h, rotating in 50 ml Falcon tubes at 4 °C.
The insoluble material was removed by centrifugation from the
solubilisate in a Ti70 rotor for 60 min at 311,000 ×g at 4 °C in an Op-
tima L-100 XP Ultracentrifuge (Beckman) and the supernatant was
transferred to 50 ml Falcon tubes. 1 ml bed volume of NiNTA-
agarose beads (QIAGEN) was pre-equilibrated by centrifugation at
1500 ×g for 5 min at 4 °C in an Eppendorf 5430 R centrifuge to re-
move the supernatant, resuspension in 2 ml of 1% LMNG, 20 mM
Tris pH 7.7, 20 mM MgCl2 and 20 mM NaCl, centrifugation for a fur-
ther 5 min at 1500 ×g and removal of the supernatant. Imidazole to
a concentration of 48 mM was added to the solubilisate, the pre-
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Fig. 1. Tetracycline resistance phenotype of TetA(B) loop deletion mutants. Deletions in
the loop between TM6 and TM7 of TetA(B) were analysed for their effect on transporter
activity by measuring the tetracycline resistance of cells expressing the mutants. The
OD600 of cultures grown in the presence of 10 μM tetracycline were compared to the
OD600 of cultures grown in the absence of tetracycline, expressed as a percentage and plot-
ted against the number of amino acid residues removed. The activity of each deletion
mutant was measured in triplicate, with error bars representing the SEM and the data
were then ﬁt with a variable slope dose–response curve. Full data and sequences of the
deletion mutants are in Supplementary Table 1.
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tating at 15 rpm for 2 h at 4 °C. The mixtures were then added to a
Fisher brand ﬁlter column in a stepwise manner and washed with
40 ml of each of 52 mM and 64 mM imidazole containing 0.003%
LMNG in the former, no LMNG in the latter and 20 mM Tris pH 7.7,
20 mM MgCl2 and 20 mM NaCl. TetA(B)His10 or TetA(B)Δ394–
401-Thrombin-His10 was eluted with 4 ml of 375 mM imidazole
containing 20 mM Tris pH 7.7, 20 mMMgCl2 and 20 mMNaCl, dialysed
for 14 h at 4 °C in 7 K cut-off SnakeSkin (Thermo Scientiﬁc) against
20 mM Tris pH 7.7, 20 mM MgCl2 and 20 mM NaCl and concentrated
in a 4 ml Amicon Ultra Ultracel 50 K cut-off concentrator in Eppendorf
5430R centrifuge at 4 °C and 1500 ×g to a volume of approximately
250 μl. The protein concentration of this partially pure sample was
then measured using an amido black assay [47].
2.10. Isothermal titration calorimetry
Isothermal titration calorimetry (ITC) was used to measure
tetracycline binding to mutants and wild type TetA(B)-His10 and
TetA(B)-Δ394–401-Thrombin-His12 that had been puriﬁed in
LMNG(see Section 2.9). An ITC200machine (Microcal)was used tomea-
sure the afﬁnities of each mutant to tetracycline. The syringe and cell
were ﬁrst washed sequentially with 5% Decon 90, distilled water and
buffer consisting of 20 mM Tris pH 7.7, 20 mM MgCl2 and 20 mM
NaCl, and dried with an applied vacuum. TheMicrocal software provid-
ed with the ITC200 machine was used to identify initial experimental
parameters using the settings “minimumprotein”with an estimated af-
ﬁnity of 5 μMand enthalpy change of−5 kJ. 280 μl of puriﬁed protein at
50 μM (diluted in the above dialysis buffer as required) was loaded in
the cell and tetracyclinemadeup at 750 μMindialysis bufferwas loaded
in the syringe. Experiments were run at 20 °C with 20 injections: the
ﬁrst injection at 0.5 μl, followed by 19 injections at 2.0 μl. The apparatus
was stirred at 1000 rpm and the delay between injections was set to
120 s. The software, Origin, was used to calculate the afﬁnity and
thermodynamic parameters for tetracycline binding to TetA(B) and
the relevant mutants.
2.11. Tetracycline transport
Membranes were produced (Section 2.8) from cells expressing
TetA(B)-His10 wild type, the mutants G44V, R70G and D285A and a
negative control of cells identically induced with IPTG, but containing
the pET21b vector and no insert. These membranes were then resus-
pended at 3.5 mg/ml total protein in 20 mM Tris pH 7.7, 20 mMMgCl2
and 20 mM NaCl, and 100 μl of membranes was used per transport
assay. Transportwas initiatedwith the addition of 10 μl tritiated tetracy-
cline (95 μM cold and 5 μM 3H-tetracycline (American Radiolabelled
Chemicals Inc, 0.07 mCi) in 20 mM Tris pH 7.7, 20 mM MgCl2 and
20 mM NaCl containing 10 mM ATP). Samples were made for each
time point, vacuum ﬁltered through aMultiscreen ﬁlter plate (Millipore
1.0 μm) prewashed with 0.1% polyethylenimine and washed three
times with 200 μl of ice cold 20 mM Tris pH 7.7, 20 mM MgCl2 and
20 mM NaCl. The ﬁlter was then dried, scintillation ﬂuid was added
and radioactivity was measured for 60 s at each time point with a Tri-
Carb 2910 TR. Each data point was performed in triplicate and ﬁt in
GraphPad Prism with a Michaelis–Menten non-linear ﬁt.
3. Results
3.1. Analysis of TetA(B) mutants with deletions in an intracellular loop
MFS transporters have a long loop between transmembrane helix 6
(TM6) and TM7, which may be important to allow the conformation
change between the outward-open and inward-open states. Shortening
of this loop may therefore constrain the conformation of a given
transporter. The loop between TM6 and TM7 in TetA(B), as predictedby the programme TMHMM [48,49], was predicted to be disordered
by the RONN disorder prediction server [50]. Deletions were therefore
made throughout this loop (Supplementary Table 1) ranging from 4
to 19 amino acid residues, avoiding residues Asp190, Glu192, Ser201
and Met210 that show reduced activity when mutated to Cys [33,51].
All deletions were made in full length TetA(B) fused at its C terminus
to enhanced GFP (eGFP) in the pBluescript SKII (+) vector. The antibi-
otic resistance phenotype of these deletionmutants was then examined
in E. coli strain JM109 by determining the MIC for tetracycline (Supple-
mentary Table 1) and then measuring the optical density of cultures
grown overnight inmedia containing 10 μMtetracycline (Fig. 1), relying
on the basal activity of the lacUV5 promoter in the absence of IPTG to
express the TetA(B) constructs. The tetracycline concentration of
10 μM was used for the latter experiment as this was the MIC for the
negative control of JM109 cells not expressing TetA(B). In-gel ﬂuores-
cence indicated that the expression level of eachmutant was not signif-
icantly affected by the deletions (data not shown). It was possible to
delete up to 6 amino acid residues and retain about 80% of the relative
resistance phenotype in comparison to TetA(B) containing the full-
length loop. However, removal of further amino acids reduced
relative tetracycline resistance levels signiﬁcantly and transporters
that contained deletions of 9 or more amino acid residues conferred
resistance to tetracycline to about 10% of the level observed with a
full-length loop (Fig. 1), despite being expressed at similar levels. This
also reduced the MIC of tetracycline to levels similar to JM109 cells
not expressing TetA(B) (Supplementary Table 1).
3.2. Isolation of non-transporting TetA(B) mutants
Point mutations were made throughout TetA(B) from Asn2 to
Ile379 using the Quickchange II methodology and expressed using
the basal activity of the lacUV5 promoter in plasmid pBluescript
(see Methods). The actual construct used, TetA(B)Δ394–401-TEV-
His10-eGFP, included a C-terminal truncation of 8 residues (Δ394-
401), a Tobacco Etch Virus (TEV) protease cleavage site, followed
by 10 histidine residues (His10) and eGFP. The 8 C-terminal residues
were predicted to be disordered by the RONN disorder prediction
server [50] and were deleted to remove a proteolysis site that
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not affect the tetracycline resistance phenotype in comparison to
the wild type transporter. Mutagenic oligonucleotide primers were
designed to change each amino acid residue between positions 2
and 379. Each amino acid codon was changed to the sequence GBC
(where B was a 1:1:1 ratio of the bases C, G and T) that introduced
the codons GCC (Ala), GGC (Gly) or GTC (Val). Thus upon mutagen-
esis and transformation of E. coli, a mixture of mutants was obtained
where each bacterial colony on a plate expressed TetA(B) that had
been mutated at a single amino acid position, but which contained
either a Val, Ala or Gly residue. It would be prohibitively expensive to
sequence every mutant, so desirable mutants were ﬁrst selected by
measuring their ability to grow on media containing tetracycline. Up
to 8 colonies were picked from each transformation to test for their re-
sistance to tetracycline, apart from amino acid positions 113, 117, 137
and 228 where no colonies were produced and position 221, 233, 237,
262, 268, 272 and 281, where fewer than 5 colonies were produced.
In total 3052 colonies were examined for their tetracycline resistance
phenotype.
The ability of each TetA(B) mutant to transport tetracycline was
assessed by measuring the ability of themutant to confer tetracycline
resistance E. coli. Interesting mutations that prevented tetracycline
transport would thus manifest themselves as not growing on
tetracycline-containing media. Each colony was therefore initially
examined using a high-throughput single point antibiotic resistance
phenotypic assay performed in 96-well plates. Growth was measured
in media containing either no tetracycline or 36 μM tetracycline and
was compared to cells either not expressing TetA(B) (negative control)
or to cells expressing wild type TetA(B) (positive control). Of 3052
colonies tested, 519 showed growth to a signiﬁcantly lower cell density
than wild type i.e. the cell density attained in 36 μM tetracycline
was less than 14% of the cell density in the absence of tetracycline1.0
0.8
0.6
0.4
0.2
0.0
0 2 5 9 18 36
[Tetracycline] (μM)
O
D 6
00
Asp15x
Ile22x
Gly44x
Vector
Wild type
Fig. 2. Selection of TetA(B) mutants that cannot confer tetracycline resistance to cells.
Mutants that conferred signiﬁcantly lowered cell density to E. coli after growth in the pres-
ence of 36 μM tetracycline were analysed over a range of tetracycline concentrations
(0 μM–36 μM). Examples of mutants are shown compared to TetA(B)Δ394-401-TEV-
His10-eGFP (black, ‘wild type’) and a negative control of cells containing vector with no
insert (red, ‘vector’). Several mutants were identiﬁed that, when re-tested, were able to
confer full tetracycline resistance (e.g. Ile22X, green), whilst others showed signiﬁcantly
lowered, but measureable resistance to tetracycline (e.g. Asp15X, orange), and some
showed growth indistinguishable with the negative control (e.g. Gly44X, blue). The super-
script ‘X’ implies that at this stage in the identiﬁcation of themutants, sequencing had not
been performed, so themutation of the deﬁned amino acid residue could have been either
to Val, Ala or Gly, or indeed another mutation could have been present elsewhere in the
coding region. Positive and negative controls were performed in duplicate and error
bars are shown (±SEM).(Supplementary Table 2). To exclude false positives, the 519 colonies
were tested further using a multipoint tetracycline resistance assay
(Fig. 2) where growth was measured in the presence of a range of
tetracycline concentrations (0 μM, 5 μM, 9 μM, 18 μM, 36 μM, 72 μM
and 144 μM). A total of 172 colonies were identiﬁed (Supplementary
Table 2) that were consistently less resistant to tetracycline than
wild type TetA(B) and were therefore examined for levels of
TetA(B) expressed.
The expression levels of TetA(B) mutants was determined by in-
gel ﬂuorescence using the C-terminal eGFP fusion [52]. This was im-
portant because a signiﬁcant reduction in the expression level of a
TetA(B) mutant would give the same loss of tetracycline resistance
phenotype to E. coli as amutation that prevents conformation chang-
es in the transporter. GFP remains ﬂuorescent even in the presence of
SDS [53], therefore SDS-PAGE was used to measure the expression
levels of each mutant by in-gel ﬂuorescence (Fig. 3). This was found
to be more reliable than measuring whole-cell ﬂuorescence. Of the
172 colonies tested, only 59 showed expression of a full-length mutant
TetA(B)-eGFP fusion to similar levels as TetA(B)-Δ394–401-TEV-His10-
eGFP and hence only these were sequenced. Of the sequencedmutants,
33 contained a single pointmutation,which represented 32 uniquemu-
tations. The minimal inhibitory concentration (MIC) for tetracycline41 
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B
Fig. 3.Measurement of TetA(B)mutant expression levels by in-gel ﬂuorescence. A, The ex-
pression levels of TetA(B)mutants that did not confer tetracycline resistance to cells were
examined by in-gelﬂuorescence. Lanes correspond to transport-compromisedmutants: 1,
T12X; 2, D15A; 3, G44V; 4, A58X; 5, G62V; 6, R70G; 7, R70A; 8, R101G; 9, R101V; 10,
A109V; 11, G139X; 12, I143A; 13, vector-only negative control (pBluescript plasmid);
14, TetA(B)-Δ394-401-TEV-His10-eGFP. After the in-gel ﬂuorescence was performed,
mutants that expressed to similar or higher levels than TetA(B)-Δ394-401-TEV-His10-
eGFP were sequenced to identify the mutation present. Those mutants that were
expressed lower than TetA(B)-Δ394-401-TEV-His10-eGFP were not sequenced, so the
mutation(s) present were not deﬁned, as indicated by the superscript ‘X’. The arrowhead
identiﬁes the full-length TetA(B)-Δ394-401-TEV-His10-eGFP fusion protein and the curly
bracket shows the position of degradation products. B, After the in-gel ﬂuorescence anal-
ysis was completed and all the mutants were sequenced, 32 individual point mutations
were identiﬁed that resulted in transport-defective TetA(B). All these mutants were re-
tested for their ability to confer tetracycline resistance to cells and only those that showed
aminimal inhibitory concentration (MIC) of tetracycline of ≤27 μMwere characterised by
ITC (green).
2266 D.J. Wright, C.G. Tate / Biochimica et Biophysica Acta 1848 (2015) 2261–2270was determined for thesemutants (Fig. 3) and the ﬁfteenmutants with
the lowest MIC (≤27 μM tetracycline) were chosen for biophysical
examination. The 15 mutations chosen were G44V, G62V, D66A,
D66G, R70G, R101G, R101V, L214G, P227V, D285A, D285G, D285V,
G336V, G346V and W369G.3.3. Isothermal titration calorimetry
The afﬁnity of TetA(B) for tetracyclinewas predicted to be in the μM
range based on the Km for transport [30,54] and therefore isothermal ti-
tration calorimetry (ITC) was used to measure the tetracycline binding
afﬁnities to the selected mutants. TetA(B)-His10 and TetA(B)-Δ394–
401-Thrombin-His10 were both puriﬁed in LMNG by Ni2+-afﬁnity
chromatography and were of sufﬁcient purity for ITC measurements
to be performed. Both constructs resulted in a similar afﬁnity (7.3 ±
0.5 μM and 10 ± 2 μM, respectively), showing that the C-terminal
truncation had no signiﬁcant effect on the binding of tetracycline to
TetA(B) (Table 1). Therefore, the 15 point mutations were transferred
to either TetA(B)-His10 (G44V, G62V, R70G, R101G, R101V, P227V,
D285A, D285G, D285V, G336V and G346V) or TetA(B)Δ394–401-
Thrombin-His12 (loop deletions and D66A, D66G, L214G and W369G)
for puriﬁcation and ITC measurements (Fig. 4, Table 1 and Supplemen-
tary Figs. 1–5).
Of the 15mutants that resulted in a tetracycline-sensitive phenotype
to E. coli, only 3 mutants (G44V, R70G and G346V) could be readily
puriﬁed and reproducibly bound tetracycline (Table 1). The mutant
R70G was particularly interesting because it bound tetracycline with a
Kd of 2.1 ± 0.9 μM, which was 3.5-fold higher afﬁnity compared to
TetA(B)-His10, whereas tetracycline bound to the mutants G44V and
G346V (Kd 28 ± 4 μM and 36 ± 16 μM, respectively) between 4-fold
and 5-fold weaker than the parental transporter. Of the remaining
mutants, G336V was not overexpressed and therefore could not be pu-
riﬁed in sufﬁcient amounts for ITC, L214G and P227V gave ambiguous
results and the remainder showed no appreciable binding of tetracy-
cline (G62V, D66A, D66G, R101G, R101V, D285A, D285G, D285V
and W369G). Two loop deletion mutants, TetA(B)-Δ195–199,203–207
(9 amino acid residues deleted) and TetA(B)-Δ182–187,195–199
(11 amino acid residues deleted), were also examined for tetracycline
binding (Fig. 5). The deletion of 9 amino acid residues resulted in only
a minor change in tetracycline afﬁnity relative to the parentalTable 1
ITC data for tetracycline binding to puriﬁed transport-defective TetA(B) mutants.
Construct Mutant Number of independent
experiments
Afﬁnity Kd
(μM)
E
(
TetA(B)-His10 3 7.3 ± 0.5 -
G44V 2 28 ± 4 -
G62V 2 No signiﬁcant bind
R70G 2 2.1 ± 0.9 2
R101G 3 No signiﬁcant bind
R101V 2 No signiﬁcant bind
P227V 2 33 ± 12 -
No signiﬁcant bind
D285A 2 No signiﬁcant bind
D285G 2 No signiﬁcant bind
D285V 2 No signiﬁcant bind
G336V No expression
G346V 2 36 ± 16 -
TetA(B)-Δ394-401-Tb-His12 2 10 ± 2 -
D66A 2 No signiﬁcant bind
D66G 2 No signiﬁcant bind
L214G 3 31 ± 12 -
No signiﬁcant bind
W369G 2 No signiﬁcant bind
Δ195–199,
203–207
2 17.5 ± 0.5 -
Δ182–187,
195–199
2 No signiﬁcant bindtransporter (Kd 17.5± 0.5 μMcompared to 10± 2 μM). However, dele-
tion of 11 amino acid residues resulted in no measureable tetracycline
binding.
3.4. Tetracycline transport of selected mutants
To further characterise selected mutants of TetA(B), H+-linked
transport of 3H-tetracycline was measured in membrane vesicles
prepared from cells expressing the transporters. The 3H-tetracycline
transport rate of TetA(B)-His10 was comparedwith the low afﬁnitymu-
tant G44V, the high afﬁnity mutant R70G, the non-tetracycline-binding
mutant D285A and a negative control of membranes containing no
over-expressed TetA(B). 3H-tetracycline transport by membranes
containing the mutant D285A was indistinguishable from the negative
control (Fig. 6). In contrast, 3H-tetracycline transport was observed in
membranes containing the mutants G44V and R70G that were still
able to bind tetracycline, although transport was considerably dimin-
ished compared to TetA(B)-His10 (Fig. 6).
4. Discussion
Crystallisation and structure determination of proton-linked MFS
transporters has made great progress over the last 15 years since the
ﬁrst structure, LacY, was determined [4–29]. However, the number of
structures that have been solved is still a tiny fraction of unique trans-
porters found in nature. One possibility to account for the difﬁculty in
crystallising MFS transporters is that there is considerable conforma-
tional heterogeneity of the puriﬁed transporter, particularly as one of
the substrates, a H+, can never be removed from solution whilst main-
taining the structure of the transporter. Thus there is little impediment
to transitions between the outward-open and inward-open states,
which inevitably makes the formation of well-diffracting crystals
problematic. Therefore the isolation of mutants of a transporter
that maintain the structure of the wild type protein and yet are
conformationally restrained would greatly facilitate structure determi-
nation. Here we showed that two systematic methodologies generated
mutants that were signiﬁcantly impaired in their ability to transport
tetracycline and yet some of these mutants could still bind tetracycline.
Deletions in the loop between TM6 and TM7 have previously been
made in LacY, the most well-studied member of the MFS family. Itnthalpy ΔH
kJ/mol)
EntropyΔS
(J/mol)
Tetracycline bound to TetA(B) N
(mol/mol)
11.6 ± 1.0 59 ± 3 1.3 ± 0.2
75.5 ± 2.5 170 ± 10 0.4 ± 0.2
ing
4 ± 1 189 ± 10 1.14 ± 0.34
ing
ing
14 ± 5 39 0.6 ± 0.2
ing
ing
ing
ing
27 ± 9 34 ± 6 1.3 ± 0.1
22 ± 1 20.5 ± 1.5 1.1 ± 0.1
ing
ing
14 ± 12 39 0.3 ± 0.2
ing (n = 2)
ing
29 ± 3 -7 ± 9 1.1 ± 0.1
ing
N      Too ambiguous
Kd    Too ambiguous
ΔH    Too ambiguous
ΔS    Too ambiguous
N      0.40 ± 0.04 sites
Kd    22 - 26 µM
ΔH   -78 ± 9 KJ/mol
ΔS   180 J/mol/oC
N      0.80 ± 0.03 sites
Kd     0.8 - 1.6 µM
ΔH    24.9 ± 1.1 KJ/mol
ΔS    199 J/mol/oC
N      Too ambiguous
Kd    Too ambiguous
ΔH    Too ambiguous
ΔS    Too ambiguous
A B C
D E F
TetA(B)-His10
G44V R70G D285V
Negative control
N      1.16 ± 0.05 sites
Kd 7 - 10 µM
ΔH  -11.2 ± 0.6 KJ/mol
ΔS    59 J/mol/oC
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80
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Fig. 4. Isothermal titration calorimetry of TetA(B) non-transporting pointmutants. A, TetA(B)-His10was puriﬁed in the detergent LMNGbyNi2+-afﬁnity chromatography and the fractions
were analysed on an SDS-PAGE gel; lane 1, ﬂow through; lane 2, ﬁrst wash; lane 3, second wash; lane 4, eluted sample. The eluted sample was concentrated and dialysed into a suitable
buffer for ITC. Similar or better levels of puritywere obtainedwith all the other TetA(B) constructs. B–F, examples of ITC data for TetA(B)mutants. Each experiment used a concentration of
50 μMTetA(B)mutant and injections of 0.5 μl–2 μl of 750 μM tetracycline. The parental TetA(B) construct used in all the experiments (except the negative control)was TetA(B)-His10. The
negative controlwas tetracycline injected into detergent solution. B, positive control, TetA(B)-His10; C, negative control; D, G44V; E, R70G; F, D285V. Results for thenumber of binding sites
(N), the afﬁnity (Kd), the change in enthalpy (ΔH) and the change in entropy (ΔS) upon tetracycline binding to each mutant was calculated from the data using the programme Origin.
Where the data were inconsistent with tetracycline binding, we have written ‘Too ambiguous’. The data for ITC experiments performed on all mutants is summarised in Table 2, with the
experimental data shown in Supplementary Figs. 1–5.
2267D.J. Wright, C.G. Tate / Biochimica et Biophysica Acta 1848 (2015) 2261–2270was observed that deletion of ﬁve residues resulted in a transporter that
was essentially indistinguishable fromwild type,whereas deletion of 12
or 20 residues resulted in a transporter that did not transport the sub-
strate lactose [55]. Deletions in the analogous loop in TetA(B) gave sim-
ilar results, with the removal of 9 or more amino acid residues resulting
in TetA(B) mutants that did not confer tetracycline resistance to cells.
Interestingly, removal of 9 amino acid residues still resulted in
a TetA(B) mutant that could bind tetracycline with similar afﬁnity to
the wild type transporter, suggesting that it could be conformationally
restrained and is thus a good candidate for structural studies.
An alternative strategy to identify potentially conformationally-
restrained transporters was to isolate point mutations in TetA(B) that
abolished the tetracycline-resistant phenotype conferred by the wildtype transporter on E. coli. Fifteen such mutants of TetA(B) were identi-
ﬁed at 11 amino acid residues throughout the transporter with similar
expression levels to the wild type transporter. Interestingly, of these
11 amino acid residues, 8 gave a similar reduced transport phenotype
when the residues were mutated to Cys [33–39] (amino acid residues
G44, G62, D66, R70, R101, D285, G336, G346), whereas 3 did not
(amino acid residues L214, P227, W369). It is striking that the majority
of these mutations are either of a Gly residue or a charged residue, sug-
gesting that scanningmutagenesis to identify transport-defectivemuta-
tions in other transporters could be streamlined by considering only
these residues. Three main causes for the effects of the mutations can
be envisaged: (1) the mutation alters an amino acid residue that
makes direct contact to tetracycline, thus signiﬁcantly lowering its
A TetA(B)-Δ394-401-Tb-His12 B TetA(B)-Δ195-199,204-207-Tb-His12
N      1.05 ± 0.04 sites
Kd 8 - 11 µM
ΔH - 21.9 ± 1.0 KJ/mol
ΔS   22 J/mol/oC
N     1.20 ± 0.04 sites
Kd   15 - 19 µM
ΔH   -32 ± 1.5 KJ/mol
ΔS   -16 J/mol/oC
Fig. 5. Isothermal titration calorimetry of TetA(B) loop deletion mutants that are transport-defective. Loop deletion mutants were constructed in TetA(B)-Δ394–401-Tb-His12; the C-
terminal deletion (Δ394–401) is not included in their names for clarity. A, positive control TetA(B)-Δ394–401-Tb-His12; B, TetA(B)-Δ195–199,204–207-Tb-His12. The data for ITC
experiments performed on other loop deletion mutants is summarised in Table 2, with the experimental data shown in Supplementary Fig. 5.
G44
W369
P227G346
2268 D.J. Wright, C.G. Tate / Biochimica et Biophysica Acta 1848 (2015) 2261–2270afﬁnity and hence abolishing substrate binding; (2) the mutation alters
an amino acid residue that is at the interface between transmembrane
helices, thus increasing the kinetic barriers between different conforma-
tional states and hence abolishing transport; (3) the mutation perturbs
the folding of the transporter so that the mutant does not attain a
correctly folded state. Ideally, each mutant should be characterised to
deﬁne the most likely effect it had on TetA(B) folding and activity,
thus identifying those mutants most likely to improve the probability
of obtaining well-diffracting crystals. To facilitate this, the positions of
the mutations were placed on a model of TetA(B) made simply from
threading the amino acid sequence on to the structure of YajR [21]
(Fig. 7). The structures of MFS transporters [4–29] show that substrates
bind invariably in the V-shaped cleft between the N-terminal and C-100 200 300 400 500 6000
0
10000
20000
30000
40000
50000
D
PM
Time (seconds)
Wild type
G44V
R70G
D285A
Negative control
Fig. 6. Tetracycline transport in inverted membrane vesicles. Inverted vesicles were pre-
pared fromwhole E. coli cells expressing each TetA(B)mutant identiﬁed that did not con-
fer tetracycline resistance. The transport of 3H-tetracycline was measured in the presence
of ATP: pink circles, wild type TetA(B); orange squares, TetA(B)-G44V; khaki green trian-
gles, TetA(B)-R70G; green inverted triangles, TetA(B)-D285A; blue diamonds, negative
control (no TetA(B) expressed).terminal halves of the protein, so if this also applies to TetA(B), then
themodel suggests that none of themutations would have had a signif-
icant direct impact upon the afﬁnity of tetracycline binding.
To differentiate between whether a given mutation results in a
misfolded transporter or a correctly folded transporter, the ability of
the mutant to bind tetracycline was measured by ITC. Three mutants
did indeed bind tetracycline, G44V, R70G and G346V, thus highlightingG62
R101
D66
R70
D285
L214
G336
Fig. 7. Predicted positions of non-transporting mutants based on a model of the
TetA(B) homolog YajR. A model of TetA(B) was built from YajR (PDB code 3wdo) [21],
using SWISS-MODEL [60] and an alignment with AlignMe [61]. The positions of non-
transporting mutants are shown in grey and labelled. The model is viewed in the
membrane plane.
2269D.J. Wright, C.G. Tate / Biochimica et Biophysica Acta 1848 (2015) 2261–2270these as useful candidates for structural studies. Of the remaining mu-
tants, it is unclear from the data whether they are correctly folded or
not. The absence of tetracycline binding does not prove that a mutant
is misfolded, because it is possible that the mutant is in an occluded
state that prevents substrate binding. In fact, circumstantial evidence
supports the possibility that these mutants may indeed be in a biologi-
cally relevant conformation given that all the mutants (except
for G336V that did not overexpress) could be puriﬁed using the very
mild detergent LMNG. Misfolded membrane proteins have a strong
propensity to aggregate in the membrane that usually prevents their
solubilisation by mild detergents such as dodecylmaltoside [56] and
also they tend to be more prone to aggregation during puriﬁcation.
However, there is no easy way to ascertain whether these mutants are
indeed folded, without extensive biophysical data, and the best way to
prove this is to see whether they crystallise (work in progress).
One cluster ofmutants, G62A, D66A, R70G andG336V,were predict-
ed to be close together in 3-dimensional space in the outward-open
model (Fig. 7). The residues Gly62, Asp66 and Arg70 and the region be-
tween TM2 and TM3, is highly conserved and has been implicated in
gating [57]. It is interesting that, although Asp66 and Arg70 are both
predicted to be involved in gating [57], the effects ofmutating these res-
idues were different and the roles of Asp66 and Arg70 are not analo-
gous. The TetA(B) mutants D66A and D66G were transport-defective
and could not bind tetracycline whereas the mutant R70G bound tetra-
cycline with high afﬁnity despite being transport-defective. The
TetA(B) mutant R70G bound tetracycline with a signiﬁcantly higher af-
ﬁnity than wild type (2.1 μM compared to 7.3 μM) and, in addition,
showedmarkedly different thermodynamic parameters for tetracycline
binding (Table 1). Interestingly, analogous resultswere observed for the
conformationally stabilised C154Gmutant of the lactose permease, LacY
[58], which was subsequently crystallised and gave the ﬁrst structure
of an MFS transporter. Similar parallels are observed between the
G44V mutant in TetA(B) and the G46W in LacY. TetA(B)-G44V was
transport-defective and yet still bound tetracycline, although with
a 4-fold reduced afﬁnity compared to the wild type transporter.
LacY-G46W was unable to transport lactose, but could still bind it,
and was instrumental in crystallising an alternative LacY conforma-
tion [9,59]. This striking parallel suggests that amore rational approach
to conformational stabilisation of MFS transporters through rational
mutagenesis may be possible, due to the conserved mechanism of
transport within this family. The work presented here is a ﬁrst step
towards this goal and suggests that the recent successes in developing
generic technologies for the crystallisation of GPCRs could bemimicked
with MFS transporters.
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